| Name | Title | Contact Details |
|---|
CompManagement Health Systems, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Watercrest Senior Living Group specializes in the development and operations of assisted living and memory care communities, market repositioning and advisory services. The principals have an impressive track record of leading the turnaround of underperforming assets and the stabilization of newly built communities. Partnering with a wide variety of stakeholders such as land owners, real estate developers, investors, financial institutions, and REITs, Watercrest Senior Living Group focuses on its core strengths, operations management of assisted living and memory care communities and the development of servant leaders. With state of the art information systems and key vendor partnerships, we are well positioned to efficiently assimilate both existing assisted living and memory care communities and the next generation of senior living product.
OrthoFX have the best materials technology in the industry, due in large part to Loc Phan, the key scientist behind developing the first ever clear aligner. We are committed to continued polymer technology innovation by hiring a team of industry experts like Loc to understand your needs and pain points, and we can`t do it without your partnership.
Transcarent is a new consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, Health Guides and data science, Transcarent empowers consumers with unbiased information, trusted guidance and access to high-value care.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.